Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional Results available

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

ClinicalTrials.gov ID: NCT03257358

Public ClinicalTrials.gov record NCT03257358. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT]

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod

Study identification

NCT ID
NCT03257358
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
382 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 18, 2017
Primary completion
Mar 4, 2019
Completion
Jun 27, 2019
Last update posted
Oct 6, 2021

2017 – 2019

United States locations

U.S. sites
66
U.S. states
29
U.S. cities
63
Facility City State ZIP Site status
Novartis Investigative Site Birmingham Alabama 35209
Novartis Investigative Site Cullman Alabama 35058
Novartis Investigative Site Tucson Arizona 85718
Novartis Investigative Site Berkeley California 94705
Novartis Investigative Site Sacramento California 95817
Novartis Investigative Site Colorado Springs Colorado 80907
Novartis Investigative Site Louisville Colorado 80027
Novartis Investigative Site Boca Raton Florida 33482
Novartis Investigative Site Boca Raton Florida 33487
Novartis Investigative Site Jacksonville Florida 32209
Novartis Investigative Site Miami Florida 33136
Novartis Investigative Site Ocala Florida 34471
Novartis Investigative Site Port Charlotte Florida 33952
Novartis Investigative Site Sarasota Florida 34243
Novartis Investigative Site Sunrise Florida 33351
Novartis Investigative Site Vero Beach Florida 32960
Novartis Investigative Site Savannah Georgia 31406
Novartis Investigative Site Suwanee Georgia 30024
Novartis Investigative Site Flossmoor Illinois 60422
Novartis Investigative Site Kansas City Kansas 66160
Novartis Investigative Site Louisville Kentucky 40202
Novartis Investigative Site Louisville Kentucky 40207
Novartis Investigative Site Lutherville Maryland 21093
Novartis Investigative Site Foxborough Massachusetts 02035
Novartis Investigative Site Lexington Massachusetts 02421
Novartis Investigative Site Wellesley Massachusetts 02481
Novartis Investigative Site Ann Arbor Michigan 48109
Novartis Investigative Site Owosso Michigan 48867
Novartis Investigative Site Golden Valley Minnesota 55422
Novartis Investigative Site Kansas City Missouri 64111
Novartis Investigative Site St Louis Missouri 63131
Novartis Investigative Site Las Vegas Nevada 89106
Novartis Investigative Site Fair Lawn New Jersey 07410
Novartis Investigative Site Livingston New Jersey 07039
Novartis Investigative Site Patchogue New York 11772
Novartis Investigative Site Plainview New York 11803
Novartis Investigative Site Asheville North Carolina 28806
Novartis Investigative Site Charlotte North Carolina 28207
Novartis Investigative Site Mooresville North Carolina 28117
Novartis Investigative Site Raleigh North Carolina 27607
Novartis Investigative Site Winston-Salem North Carolina 27103
Novartis Investigative Site Cleveland Ohio 44195
Novartis Investigative Site Dayton Ohio 45408
Novartis Investigative Site Toledo Ohio 43623
Novartis Investigative Site Westerville Ohio 43081
Novartis Investigative Site Oklahoma City Oklahoma 73102
Novartis Investigative Site Oklahoma City Oklahoma 73104
Novartis Investigative Site Portland Oregon 97225
Novartis Investigative Site Philadelphia Pennsylvania 19140
Novartis Investigative Site Greer South Carolina 29650
Novartis Investigative Site Mt. Pleasant South Carolina 29464
Novartis Investigative Site Port Royal South Carolina 29935
Novartis Investigative Site Knoxville Tennessee 37922
Novartis Investigative Site Nashville Tennessee 37215
Novartis Investigative Site Dallas Texas 75246
Novartis Investigative Site San Antonio Texas 78258
Novartis Investigative Site Falls Church Virginia 22043
Novartis Investigative Site Vienna Virginia 22182
Novartis Investigative Site Kirkland Washington 98034
Novartis Investigative Site Seattle Washington 98122
Novartis Investigative Site Spokane Washington 99202
Novartis Investigative Site Tacoma Washington 98405
Novartis Investigative Site Huntington West Virginia 25701
Novartis Investigative Site Green Bay Wisconsin 54311
Novartis Investigative Site Milwaukee Wisconsin 53215
Novartis Investigative Site Neenah Wisconsin 54956

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03257358, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 6, 2021 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03257358 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →